A kind of Lactobacillus plantarum ZJUF SYS1 and its application

Through the ZJUF SYS1 plantarum ZJUF SYS1 isolated from Sichuan kimchi, the existing constipation treatment methods have not fundamentally solved the problem of constipation problems. Through its good gastrointestinal environment tolerance and self-aggregation ability, constipation is significantly alleviated. A new drug or functional food regimen is provided.

CN115960784BActive Publication Date: 2024-11-05HANGZHOU KANGYUAN FOOD SCI & TECH +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211720993.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-30
Publication Date
2024-11-05
Estimated Expiration
2042-12-30

AI Technical Summary

Technical Problem

Most of the existing constipation treatment methods are symptomatic treatments, which cannot fundamentally solve the problem of constipation. Moreover, there are uncertain efficacy and adverse reactions in drug treatment, so traditional drugs are difficult to effectively relieve functional constipation.

Method used

A new strain of Lactipani plantarum ZJUF SYS1 was isolated from Sichuan kimchi. It has good gastrointestinal environmental tolerance and self-aggregation ability. It can effectively inhibit pathogenic bacteria and promote intestinal peristalsis and increase feces water content. To relieve constipation.

Benefits of technology

Lactobacillus plantarum ZJUF SYS1 significantly accelerates intestinal peristalsis, shortens the discharge time of the first black stool, increases the number and water content of feces, effectively relieves constipation, and provides a new application solution for drugs or functional foods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115960784B_ABST
    Figure CN115960784B_ABST
Patent Text Reader

Abstract

The present invention discloses a Lactobacillus plantarum ZJUF SYS1 and an application thereof, and belongs to the field of microbial technology. The deposit number of the Lactobacillus plantarum ZJUF SYS1 is CCTCC NO:M 2022662. The present invention also provides an application of the Lactobacillus plantarum ZJUF SYS1 in the preparation of a medicine for relieving constipation and inhibiting gastrointestinal pathogens. The Lactobacillus plantarum ZJUF SYS1 can effectively relieve constipation, and the strain has good tolerance in the gastrointestinal environment, can achieve intestinal efficacy, effectively inhibit gastrointestinal pathogens from colonizing in the gastrointestinal tract, and is beneficial to intestinal health. The present invention provides an effective probiotic strain for constipation treatment, which is of great significance to the development of constipation treatment drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, and in particular to a Lactobacillus plantarum (Lactiplantibacillus plantarum) ZJUF SYS1 and an application thereof. Background Art

[0002] According to the Rome III diagnostic criteria for constipation, the symptoms of functional constipation are less than 3 bowel movements a week, or bowel movements more than 3 days apart, accompanied by abnormal stool shape, straining during bowel movements or incomplete bowel movements, and not meeting the diagnostic criteria for irritable bowel syndrome. Long-term constipation can easily induce diseases such as hemorrhoids and anal fissures, making it more difficult to cure constipation and making patients easily lose confidence in treatment.

[0003] There are many causes of constipation. Studies have found that intestinal microecology is involved in the occurrence and development of constipation. A common intestinal flora feature of constipation patients is the presence of severe flora disorder. Stool hardness is negatively correlated with the abundance of intestinal flora. One-third of the stool in the human intestine is bacteria, and two-thirds is food residue. The intestinal flora ferments food residues to soften the stool, but work pressure or bad living habits can cause a person's intestinal flora to be insufficient, and the inability to ferment normally causes the stool to become hard. In addition, intestinal flora imbalance affects colon peristalsis, inhibits intestinal movement, and promotes constipation. In recent years, many studies have found that mental and psychological factors have a significant impact on the occurrence and clinical manifestations of functional constipation, and there is a significant correlation between morbid behavior, emotional disorders and gastrointestinal transit time.

[0004] At present, the treatment of constipation includes conventional therapies such as improving eating habits and increasing dietary fiber intake, the use of laxatives, prokinetics, secretagogues and other drugs, traditional Chinese medicine, and biofeedback therapy using scientific instruments. Among these, drug therapy is the most commonly used and feasible prevention and treatment method, but the problems gradually revealed in the clinical application of drug treatment of various types of constipation cannot be ignored, such as the efficacy needs to be further observed, and the adverse drug reactions gradually appear. For example, the long-term use of neurostimulant laxatives such as rhubarb, senna leaves, and aloe vera can lead to colon melanosis, weakened intestinal peristalsis, and smooth muscle atrophy.

[0005] Traditional medication is mostly symptomatic treatment, and there is no way to fundamentally solve the problem of constipation. Oral probiotics are one of the main auxiliary treatment methods in current clinical drug treatment plans. Live bacterial preparations do not need to be absorbed through the body, are not likely to cause adverse reactions, and have many physiological benefits. Probiotics are an important part of microbial preparations. Currently, the main types of bacteria used to relieve constipation are bifidobacteria, lactic acid bacteria, and enterococci.

[0006] Lactobacillus plantarum is a type of lactic acid bacteria. Lactobacillus plantarum has the property of fermenting acid to reduce the pH value of the intestine and is an excellent strain for potentially relieving constipation. For example, patent documents CN 113564084 A, CN 110692726A, CN 110699271A, etc. report the use of Lactobacillus plantarum in relieving constipation.

[0007] Since there are great differences in the genomes and functions of different strains of Lactobacillus plantarum, discovering more Lactobacillus plantarum that are beneficial for relieving constipation is a problem that technicians in this field need to solve. Summary of the invention

[0008] The purpose of the present invention is to provide a new Lactobacillus plantarum strain that can effectively treat functional constipation, and to use the strain in the development of medicines or functional foods for relieving constipation.

[0009] To achieve the above object, the present invention adopts the following technical solution:

[0010] The invention separates and obtains a new probiotic strain from Sichuan pickles. The strain is identified as Lactobacillus plantarum through microbiological property analysis and 16S rRNA gene comparison analysis, so the strain is named as Lactobacillus plantarum ZJUF SYS1.

[0011] Lactobacillus plantarum ZJUF SYS1 was deposited in the China Center for Type Culture Collection (Address: Wuhan University, Wuhan, China) on May 18, 2022, with the accession number: CCTCC NO:M 2022662.

[0012] Through in vitro simulated gastrointestinal environment resistance studies, it was found that the viable bacterial count survival rate of Lactobacillus plantarum ZJUF SYS1 in an acidic environment with a pH of 2.5 after 3 hours was 97.06%, and the survival rate reached 65.95% after 8 hours in a simulated intestinal fluid containing 1.8% bile salts, indicating that the Lactobacillus plantarum ZJUF SYS1 provided by the present invention has good tolerance in the gastrointestinal environment and can reach the intestine to exert its efficacy.

[0013] Through the self-agglutination experiment, it was found that the self-agglutination rate of Lactobacillus plantarum ZJUF SYS1 to 22h was as high as 78%, which was significantly higher than that of the model strain LGG, indicating that it has a strong ability to adhere to the intestine and is easy to form a probiotic biofilm, thereby protecting the body.

[0014] Through the interactive agglutination experiment, it was found that the agglutination rate between Lactobacillus plantarum ZJUF SYS1 and pathogens (Escherichia coli, Salmonella typhimurium and Staphylococcus aureus) increased with time. In particular, the agglutination rate between this probiotic and Staphylococcus aureus was significantly higher than that of LGG, indicating that Lactobacillus plantarum ZJUF SYS1 can agglutinate well with pathogenic bacteria in the intestines and be successfully excreted from the body, which is beneficial to intestinal health.

[0015] Therefore, the present invention provides the use of Lactobacillus plantarum ZJUF SYS1 in preparing a medicament for inhibiting gastrointestinal pathogens.

[0016] Furthermore, Lactobacillus plantarum ZJUF SYS1 inhibits the colonization of gastrointestinal pathogens in the gastrointestinal tract by agglutinating with gastrointestinal pathogens, which is beneficial to intestinal health.

[0017] Specifically, the gastrointestinal pathogenic bacteria include one or more of Escherichia coli, Salmonella typhimurium, and Staphylococcus aureus.

[0018] The present invention further verifies that Lactobacillus plantarum ZJUF SYS1 has a good constipation relief effect through zebrafish constipation model and mouse constipation model. Specifically, in the zebrafish constipation model, the intervention of Lactobacillus plantarum ZJUF SYS1 can significantly accelerate intestinal peristalsis, and its peristalsis speed is close to that of the normal group. This result is not significantly different from the effect of the positive control metoclopramide. In the mouse constipation model, after the intervention of Lactobacillus plantarum ZJUF SYS1, the intestinal peristalsis of constipated mice was significantly accelerated, which was mainly manifested in the significant shortening of the first black stool discharge time and the significant increase in the number of fecal particles to normal levels. In addition to promoting intestinal peristalsis, the intervention of Lactobacillus plantarum ZJUF SYS1 restored the fecal water content of constipated mice to normal levels.

[0019] Therefore, the present invention provides the use of Lactobacillus plantarum ZJUF SYS1 in preparing medicines or functional foods for alleviating constipation.

[0020] Furthermore, the Lactobacillus plantarum ZJUF SYS1 relieves constipation by promoting intestinal peristalsis and increasing the water content of feces.

[0021] Furthermore, the constipation is functional constipation.

[0022] The plant lactobacillus ZJUF SYS1 of the present invention can be used to prepare a pharmaceutical composition. The pharmaceutical composition contains a pharmaceutically effective dose of live bacteria of the plant lactobacillus ZJUF SYS1. In addition, the pharmaceutical composition may also contain a suitable pharmaceutical carrier. The pharmaceutical composition of the present invention may be in the form of capsules, solutions or drinkable suspensions, bagged powders, etc. Each single dose generally contains about 10 Lactobacillus plantarum ZJUF SYS1 strains. 7 ~10 10 The pharmaceutical composition of the present invention can be used to prevent and treat constipation-related diseases.

[0023] Specifically, the present invention provides a pharmaceutical composition for preventing or treating constipation, comprising an effective dose of Lactobacillus plantarum ZJUF SYS1 and a pharmaceutically acceptable carrier.

[0024] Preferably, the effective dose of active Lactobacillus plantarum ZJUF SYS1 contained in the pharmaceutical composition is 10 7 ~10 10 CFU.

[0025] Preferably, the pharmaceutical composition is in the form of an oral preparation.

[0026] The Lactobacillus plantarum ZJUF SYS1 of the present invention can also be prepared into foods, health products or food ingredients, and these foods, health products or food ingredients can be used to prevent and treat constipation and improve the health level of users.

[0027] Specifically, the present invention provides a functional food or food ingredient for relieving constipation, comprising Lactobacillus plantarum ZJUF SYS1 and a food-acceptable auxiliary material.

[0028] The food may be in the form of fermented milk, fermented fruits and vegetables, enzymes, composite preparations, etc., containing the live bacteria of Lactobacillus plantarum ZJUFSYS1 of the present invention.

[0029] The present invention has the following beneficial effects:

[0030] The present invention provides a new Lactobacillus plantarum ZJUF SYS1, which has good tolerance in the gastrointestinal environment and can achieve intestinal efficacy. The self-aggregation ability and interactive gel ability of Lactobacillus plantarum ZJUF SYS1 with gastrointestinal pathogens are significantly higher than those of the model bacteria Lactobacillus rhamnosus, inhibiting the colonization of gastrointestinal pathogens in the gastrointestinal tract, which is beneficial to intestinal health. Through zebrafish constipation model and mouse constipation model, it was found that Lactobacillus plantarum ZJUF SYS1 can effectively relieve constipation. The present invention provides an effective probiotic strain for constipation treatment, which is of great significance to the development of constipation treatment drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Figure 2 is the self-agglutination property of Lactobacillus plantarum ZJUF SYS1 and its cross-agglutination property with pathogenic bacteria, where A is the self-agglutination rate of probiotics, B is the cross-agglutination rate between probiotics and Escherichia coli, C is the cross-agglutination rate between probiotics and Salmonella typhimurium, and D is the cross-agglutination rate between probiotics and Staphylococcus aureus. In the figure, * represents p < 0.05, and ** represents p < 0.01.

[0032] Figure 2 The figure shows the effect of Lactobacillus plantarum ZJUF SYS1 on intestinal peristalsis of zebrafish. Different letters such as a and b in the figure represent significant differences among the groups (p<0.05).

[0033] Figure 3 To compare the effects of Lactobacillus plantarum ZJUF SYS1 and other Lactobacillus plantarum on intestinal motility in zebrafish, * indicates comparison with the CON group, ** indicates p < 0.01; # indicates comparison with the LOP group, # indicates p < 0.05, and ## indicates p < 0.01.

[0034] Figure 4 To compare the effects of Lactobacillus plantarum ZJUF SYS1 and Bifidobacterium BB12 on intestinal motility in zebrafish, * indicates comparison with the CON group, ** indicates p < 0.01; # indicates comparison with the LOP group, # indicates p < 0.05, and ## indicates p < 0.01.

[0035] Figure 5 The figures show the energy intake and weight gain of mice in each group of the mouse experiment, where A represents energy intake and B represents weight gain. Different letters such as a and b in the figure represent significant differences among the groups (p<0.05).

[0036] Figure 6 The figures show the defecation and small intestinal propulsion of mice, where A is the time of the first black stool excretion, B is the number of stool particles within 5 hours, C is the wet weight of feces within 5 hours, D is the dry weight of feces within 5 hours, and E is the moisture content of feces. Different letters such as a and b in the figure indicate significant differences among the groups (p < 0.05). DETAILED DESCRIPTION

[0037] The present invention will be further described below in conjunction with specific embodiments. The following embodiments are only used to illustrate the present invention and are not intended to limit the scope of application of the present invention. Without departing from the spirit and essence of the present invention, modifications or replacements made to the inventive method, steps or conditions all belong to the scope of the present invention.

[0038] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.

[0039] Example 1: Screening, Isolation and Identification of Lactobacillus plantarum ZJUF SYS1

[0040] (1) Screening and isolation of strains:

[0041] Take 5g Sichuan pickles and add them to 45mL 0.85% sterile saline, shake well, and dilute to 10% with saline. -5 , 10 -6 , 10 -7 , respectively, spread on MRS medium, and make 3 parallels for each gradient. Place the coated plate in an anaerobic box and culture at 37℃ for 24-48h. Select colonies with obvious differences and streak them on MRS solid medium, culture them anaerobically at 37℃ for 24-48h, and streak them 3-5 times continuously. Pick a single colony for hydrogen peroxide titration experiment. If the single colony produced bubbles on a slide with 5% hydrogen peroxide solution, it was positive for catalase test. If no bubbles were produced, it was negative for catalase test. The negative strains were suspected to be probiotic strains.

[0042] (2) Strain identification:

[0043] The suspected probiotic strain ZJUF SYS1 was subjected to Gram staining and 16S rRNA gene bacterial species identification, which was completed by Shanghai Paisonno Biological Co., Ltd.

[0044] The base sequence of 16S rRNA of ZJUF SYS1 is shown in SEQ ID NO. 1. Combining biological characteristics and 16S rRNA gene comparison, ZJUF SYS1 was confirmed to be a strain of Lactobacillus plantarum, and was named Lactobacillus plantarum ZJUF SYS1.

[0045] Lactobacillus plantarum ZJUF SYS1 was deposited in the China Center for Type Culture Collection (Address: Wuhan University, Wuhan, China) on May 18, 2022, with the accession number: CCTCC NO: M2022662, and was identified as alive on May 25, 2022.

[0046] Example 2: In vitro probiotic performance test of Lactobacillus plantarum ZJUF SYS1

[0047] (1) Simulating artificial gastrointestinal tolerance

[0048] Simulated gastric fluid (GJ): Pepsin (1:10000) was added to PBS (pH 2.5) at a concentration of 3.5 g / L.

[0049] Simulated intestinal fluid (IJ): NaHCO3 11g / L, NaCl 2g / L, trypsin 1g / L, porcine bile salt 18g / L, pH adjusted to 8.0, filtered and sterilized with 0.22μm membrane for later use.

[0050] After freezing centrifugation, live cells were obtained and washed twice with PBS (pH 7.4) to adjust the live cell concentration to about 10 9 CFU / mL, add 0.5mL of bacterial suspension to 4.5mL of simulated gastric fluid, count by MRS agar pour plate method, and place in anaerobic incubator at 37℃. After 3h, take samples and count by MRS agar pour plate counting method. After 3h of GJ treatment, take 0.5mL of GJ culture solution and add it to 4.5mL of IJ. After 8h, count by MRS agar pour plate method, and place in anaerobic incubator at 37℃ for 24-48h. Do three parallels for each strain.

[0051] Survival rate (%) = logα / logβ×100%

[0052] Note: α = number of viable lactic acid bacteria after treatment with simulated gastrointestinal fluid, β = number of viable lactic acid bacteria before treatment.

[0053] The results are shown in Table 1. Lactobacillus plantarum ZJUF SYS1 has good gastrointestinal transport ability, with a survival rate of 97.06% after digestion in gastric juice (pH 2.5), a survival rate of 65.95% after simulated intestinal juice, and a survival rate of 64.01% in the entire gastrointestinal process, which is close to that of the model bacteria Lactobacillus rhamnosus (LGG).

[0054] Table 1

[0055]

[0056] (2) Self-agglutination and cross-agglutination

[0057] Use PBS to prepare a concentration of 108 CFU / mL of bacterial solution, take 10 8 4 ml of bacterial suspension with CFU / mL was added to a sterile centrifuge tube, and 200 ul of the supernatant was taken and added to a 96-well plate at 0, 2, 4, 8, 12, and 22 h of static state, and the absorbance was measured at 600 nm. The autoagglutination rate was calculated according to the formula.

[0058] Self-agglutination rate (%) = (A0-A t ) / A0×100%

[0059] A0: OD value of the sample at 0h; A t : OD values ​​of samples at different time periods.

[0060] The test probiotic strains and pathogenic bacteria (Escherichia coli, Salmonella typhimurium and Staphylococcus aureus) were activated and cultured for 18 h. The cultures were centrifuged at 5000 rpm for 5 min, and the bacterial cell pellets were washed with sterile PBS buffer. The OD 600 The value of the test probiotic strain was 0.50±0.05. The same amount (500 μL) of the test probiotic strain was mixed with the three pathogenic bacterial cell suspensions, fully shaken for 5 minutes, and cultured at 37°C. After 2h, 4h, 8h, and 16h of static culture, 200 μL of the upper clear liquid was added to a 96-well plate, and the absorbance was measured at 600nm. The cross-agglutination rate was calculated according to the formula.

[0061] Cross-agglutination rate (%) = [(A pat +A lab )-2×A mix ] / (A pat +A lab )×100%

[0062] A pat and A lab : OD value of pathogens and probiotics at 0h; A mix : OD values ​​of the mixed solution at different time periods.

[0063] The results of self-agglutination are Figure 1 As shown in A, agglutination is the adhesion between cells, and the self-aggregation force (Autoaggregation) between cells of the same strain is a biological property related to its intestinal adhesion ability and its ability to form beneficial biofilm in the intestinal tract. The stronger the self-aggregation force of lactic acid bacteria, the stronger the adhesion ability to the intestinal tract, the easier it is to form a beneficial biofilm, and then protect the body. It was found by the self-aggregation experimental result that as time goes by, the strains will self-aggregate and precipitate. By 22h, the self-aggregation rate of plant lactobacillus ZJUF SYS1 strain reached 78%, which was significantly higher than the model strain LGG.

[0064] The results of cross-agglutination between probiotics and pathogens are as follows Figure 1 As shown in B-1D, the agglutination rate of plant lactobacillus ZJUF SYS1 with pathogens increased with the extension of time. Before 8 hours, the cross-agglutination rate of LGG with Escherichia coli was higher than that of ZJFU SYS1. At 8 hours, the agglutination rate of ZJFU SYS1 with Staphylococcus aureus was significantly higher than that of LGG with the pathogen. The cross-agglutination rate of plant lactobacillus ZJUF SYS1 with Salmonella was similar to that of LGG, with no significant difference. The cross-agglutination of probiotics can make them agglutinate with pathogens in the intestines well and be excreted smoothly, which is beneficial to intestinal health.

[0065] Example 3: Evaluation of the constipation-relieving effect of Lactobacillus plantarum ZJUF SYS1 in a zebrafish constipation model

[0066] In this example, a constipation zebrafish model was used to evaluate the constipation-relieving ability of Lactobacillus plantarum ZJUF SYS1. The genetic similarity between zebrafish and humans is as high as 87%, and the intestines are also very similar to humans. Therefore, loperamide hydrochloride (Lop) was used to successfully create a constipation model.

[0067] 1. Comparison of the effects of Lactobacillus plantarum ZJUF SYS1 on constipation at different concentrations

[0068] After 12 hours of development, zebrafish embryos were transferred to a 6-well plate with a pipette. Twenty zebrafish embryos and 6 mL of embryo culture medium containing phenylthiourea (1 mL of embryo culture medium contained 10 μL of phenylthiourea stock solution) were added to each well. 3 mL of the newly prepared mixture of phenylthiourea and embryo culture medium was replaced every other day and cultured for 2 days. After the zebrafish developed to the 5th day, the mixture of phenylthiourea and embryo culture medium in each well was removed, and 6 mL of the test sample of different concentrations was added to each experimental group. The control group (CON) was a blank control and E3 zebrafish culture system water was added. The model group (LOP) was added with 10 ug / mL loperamide hydrochloride (Lop). The experimental group LOP-AC was 10 ug / mL Lop and 50 ug / mL positive drug domperidone (AC). The experimental group LOP-LGG(8) was 10 ug / mL Lop and 10 8 CFU / mL Lactobacillus rhamnosus (LGG), experimental group LOP-SYS1 (8) was 10ug / mL Lop and 10 8 CFU / mL ZJUF SYS1, experimental group LOP-SYS1 (7) was 10ug / mL Lop and 10 7 CFU / mL ZJUF SYS1, experimental group LOP-SYS1 (6) was 10ug / mL Lop and 10 6CFU / mL ZJUF SYS1. Each group was divided into 3 parallels. After 24 hours of drug treatment, the intestinal peristalsis of zebrafish was recorded by microscopic video.

[0069] The observations were recorded under a microscope, and the time required between the two peristaltic peaks corresponding to the fourth segment of the zebrafish posterior vesicle (called the time of the first peristaltic peak appearance) was recorded. Image analysis was performed using software to compare the differences in zebrafish intestinal peristalsis speed between different drug treatment groups and the blank control group and modeling group.

[0070] The experimental results are as follows Figure 2 As shown in the results of the zebrafish model, after using Lop modeling, the first peristaltic peak of the zebrafish intestine was significantly slowed down compared with the blank control, and at a concentration of 10 8 CFU / mL and 10 7 The intervention of Lactobacillus plantarum ZJUFSYS1 at a CFU / mL dose can significantly accelerate intestinal peristalsis, and its peristalsis speed is close to that of the normal group. Its ability to relieve constipation has no significant difference from domperidone, while the model bacteria LGG does not show this effect.

[0071] 2. Comparison of the effects of different Lactobacillus plantarum strains on constipation relief

[0072] This experiment compared the constipation-relieving ability of Lactobacillus plantarum ZJUF SYS1 with other Lactobacillus plantarum strains. The strains compared were Lactobacillus plantarum YSHM1, ZW, MYN8, HN9, and YJ24, all of which were isolated by the research group in the early stage. YSHM1, ZW, and YJ24 were all isolated from Sichuan pickles, and MYN8 was isolated from Yunnan cheese. Gene comparison analysis identified them as Lactobacillus plantarum; HN9 can be found in the Chinese patent application number 201711404582.X.

[0073] The treatment method of zebrafish constipation model was the same as above. The experimental groups were set up as follows: the control group (CON) was a blank control, and E3 zebrafish culture system water was added; the model group (LOP) was added with 10ug / mL loperamide hydrochloride (Lop); the experimental group LOP-AC was 10ug / mL Lop and 50ug / mL positive drug domperidone (AC); each probiotic intervention group (LOP-YSHM1, LOP-ZW, LOP-MYN8, LOP-HN9, LOP-YJ24) was 10ug / mL Lop and 10 8 CFU / mL of each Lactobacillus plantarum.

[0074] Each group was divided into 3 parallel groups. After 24 hours of drug treatment, the intestinal peristalsis of zebrafish was recorded by microscopic video recording using the same method as above.

[0075] The experimental results are as follows Figure 3As shown in the figure, the results of the zebrafish model showed that after using Lop modeling, the first peristaltic peak of the zebrafish intestine was significantly slowed down compared with the blank control. Compared with the Lop modeling group, the intervention of Lactobacillus plantarum ZJUF SYS1 can significantly accelerate intestinal peristalsis. Compared with several other groups of Lactobacillus plantarum (including Lactobacillus plantarum YSHM1, ZW, MYN8, HN9, and YJ24), the intestinal peristalsis effect after intervention with Lactobacillus plantarum ZJUF SYS1 has a significant advantage.

[0076] 3. Comparison of the constipation-relieving effects of Lactobacillus plantarum ZJUF SYS1 and Bifidobacterium BB12

[0077] Bifidobacterium BB12 is a probiotic widely recognized for its constipation-relieving effect. This experiment used a zebrafish constipation model to compare the constipation-relieving effects of Lactobacillus plantarum ZJUF SYS1 and Bifidobacterium BB12. The BB12 used in this experiment was produced by Chr. Hansen A / S of Denmark.

[0078] The zebrafish constipation model was treated in the same way as above. The experimental groups were set up as follows: the control group (CON) was a blank control, and E3 zebrafish culture system water was added; the model group (LOP) was added with 10ug / mL loperamide hydrochloride (Lop); the experimental group LOP-AC was 10ug / mL Lop and 50ug / mL positive drug domperidone (AC); the experimental groups LOP-SYS1(8), LOP-SYS1(7), and LOP-SYS1(6) were 10ug / mL Lop and 10ug / mL respectively. 8 , 10 7 , 10 6 CFU / mL ZJUF SYS1, experimental groups LOP-BB12(8), LOP-BB12(7), LOP-BB12(6) were 10ug / mL Lop and 10 8 , 10 7 , 10 6 CFU / mL BB12.

[0079] Each group was divided into 3 parallel groups. After 24 hours of drug treatment, the intestinal peristalsis of zebrafish was recorded by microscopic video recording using the same method as above.

[0080] The experimental results are as follows Figure 4 As shown, it can be found that in 10 8 CFU / mL dose, BB12 slightly promoted intestinal motility compared with SYS1, while at 10 7 CFU / mL and 10 6 The intestinal motility promoting effect of Lactobacillus plantarum SYS1 was better than that of Bifidobacterium BB12 at the dose of 10 CFU / mL, especially at 7 At the CFU / mL dose, its intestinal motility-promoting effect is still significant.

[0081] Example 4: Evaluation of the constipation-relieving effect of probiotics in a mouse constipation model

[0082] (1) Preparation of bacterial powder

[0083] The activated Lactobacillus plantarum ZJUF SYS1 was inoculated into a sterile MRS liquid medium at a 1% inoculum volume, cultured at 37°C for 24 hours, centrifuged at 5000 rpm to obtain the bacterial cells, and resuspended the bacterial cells with a sterilized mixed solution containing 5% skim milk powder and 5% lactose as a freeze-drying protective agent, and placed in a freeze dryer for freeze drying. Finally, the pour plate method was used to count the bacterial powder obtained after freeze drying.

[0084] (2) Experimental feeding and grouping

[0085] Thirty-six healthy male BALB / C mice aged 6 weeks were placed in an animal room and fed with a normal diet for 7 days to adapt to the experimental environment (12h day / night). After the equilibrium period, they were randomly divided into 3 groups, namely the normal group (CON, gavage with sterile saline for 16 days, 2 times / day, gavage with sterile saline 10mg / kg.bw starting at 10:00 every day, and gavage with sterile saline 0.20mL / time half an hour later), the model group (LOP, gavage with loperamide hydrochloride 10mg / kg.bw starting at 10:00 every day, 1 time / day, gavage with sterile saline 0.20mL / time half an hour later), and the intervention group (LOP-SYS1, gavage with loperamide hydrochloride 10mg / kg.bw starting at 10:00 every day, 1 time / day, gavage with Lactobacillus plantarum ZJUF SYS1 half an hour later, 5*10 10 CFU / mL, 0.20mL / time). There were 12 mice in each group, divided into 3 cages, 4 mice in each cage, in an environment (22±2℃), with a humidity of 30-70%. The mice were free to eat and drink water, and their body weight and food intake were recorded once every 4 days. On the 14th day, the first black stool experiment and the number of stool particles within 5 hours were conducted. The methods used in this animal experiment were reviewed and approved by the Ethics Committee of Zhejiang Chinese Medical University (No20220425-28).

[0086] (3) Mouse defecation experiment

[0087] The mouse defecation experiment was performed on the 14th day after gavage. The detection method is as follows: On the evening of the 13th day of the experiment, the mice were fasted but not watered for 16 hours. On the 14th day of the experiment, each group was gavaged with 10 mg / kg.bw of loperamide hydrochloride, and the blank control group was gavaged with the same volume of distilled water. 0.5 hours later, the blank group and the model control group were gavaged with ink, and the sample group was gavaged with ink solution containing the corresponding content, and the timing was started. The mice were placed in a metabolic cage and immediately resumed normal diet. Observe and record the time of the first black stool of each mouse. The first black stool time of the last mouse in the model group was the termination time. The treatment group that exceeded the first black stool time of the model group was invalid. Collect feces within 5 hours and analyze the number of feces, the total weight of feces within 5 hours (wet weight) and the water content of feces.

[0088] Body weight and energy intake results Figure 5 As shown in the figure, body weight and energy intake are important indicators for studying the growth of mice. Data statistics were performed on the 16th day. Figure 5 A and 5B are the average daily energy intake and weight gain values ​​of mice, respectively. During the experimental period, there was no significant difference in the energy intake of mice in each group, while the weight gain of the model group was significantly lower than that of the normal control group. After the intervention of Lactobacillus plantarum ZJUF SYS1, there was no significant difference in weight gain between the model group and the normal group.

[0089] The time of first black stool, number of stool particles in 5 hours, dry and wet weight, and feces moisture content are the most intuitive indicators for evaluating mouse constipation. The experimental results are as follows Figure 6 As shown. Compared with the normal control group, the time of the first black stool in mice after LOP modeling was significantly prolonged, the number of fecal particles within 5 hours was significantly reduced, the fecal water content was significantly reduced, and the fecal wet weight was significantly reduced, indicating that LOP successfully created a constipation model in mice. After intervention with Lactobacillus plantarum ZJUF SYS1, the intestinal peristalsis of constipated mice was significantly accelerated, mainly manifested in a significant shortening of the time of the first black stool and a significant increase in the number of fecal particles to normal levels. In addition to promoting intestinal peristalsis, the intervention of Lactobacillus plantarum ZJUF SYS1 restored the fecal water content of constipated mice to normal levels.

Claims

1. A Lactobacillus plantarum ( Lactiplantibacillus plantarum )ZJUF SYS1, characterized in that, The preservation number of the plant lactobacillus is CCTCC NO:M 2022662.

2. The plant lactobacillus as claimed in claim 1 ( Lactiplantibacillus plantarum )Application of ZJUF SYS1 in the preparation of drugs for inhibiting gastrointestinal pathogens.

3. The use according to claim 2, characterized in that The gastrointestinal pathogenic bacteria include one or more of Escherichia coli, Salmonella typhimurium, and Staphylococcus aureus.

4. The plant lactobacillus as claimed in claim 1 ( Lactiplantibacillus plantarum )Application of ZJUF SYS1 in preparing medicine or functional food for relieving constipation.

5. The use according to claim 4, characterized in that The constipation is functional constipation.

6. A pharmaceutical composition for preventing or treating constipation, characterized in that: Comprising an effective dose of the plant lactobacillus as claimed in claim 1 ( Lactiplantibacillus plantarum )ZJUF SYS1 and a pharmaceutically acceptable carrier.

7. The pharmaceutical composition according to claim 6, characterized in that The pharmaceutical composition contains active Lactobacillus plantarum ( Lactiplantibacillus plantarum )The effective dose of ZJUF SYS1 is 10 7 ~10 10 CFU.

8. The pharmaceutical composition according to claim 6, characterized in that The pharmaceutical composition is in the form of an oral preparation.

9. A functional food or food ingredient for relieving constipation, characterized in that: comprising the plant lactobacillus as claimed in claim 1 ( Lactiplantibacillus plantarum )ZJUF SYS1 and food acceptable excipients.